BioHarvest Sciences Inc. Achieves Critical Milestones in the BioFarming of Cannabis
Staying on course for the commercialization of Cannabis & Hemp Products in the first half of 2022
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2021) - BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) announces today that it has successfully performed certain critical tasks necessary for the completion of its Cannabis development program. The Company has been adapting its unique and proprietary BioFarming technology, which enables the production of cannabinoids without growing the cannabis plant itself. Despite the many challenges caused by the Covid 19 pandemic, the Company's dedicated R&D team has stayed the course in its quest to bring to the world Cannabis-based products that will be leading edge in quality, consistency, and cleanliness at a uniquely competitive cost. BioHarvest expects to commercialize its first Cannabis-based products in the first half of 2022.
Throughout the development program, the Company has communicated multiple important milestones that not only demonstrate the feasibility of using BioHarvest's proprietary BioFarming technology for the production of Cannabis, but also the unique capabilities and knowledge of its R&D team. No other company has been able to grow Cannabis trichomes in liquid media. While other academic institutions have spent significant time and resources in this endeavor, none have been able to accomplish this major milestone, which is critical for utilizing biotech processes to produce Cannabis at industrial scale.
In February 2021, BioHarvest announced its unique scientific ability to optimize the production of trichomes in liquid media. This is critical as the trichome is the micro-factory that produces cannabinoids, flavonoids, and terpenes.
Over the course of the last three months, the Company has achieved a number of significant milestones including:
- Measurement Methods - BioHarvest has developed the required baseline scientific measurement methods to be able to evaluate the level of cannabinoids in its unique composition of cells with trichomes. There is no known industry standard in this regard, and given that BioHarvest's contribution is both novel and pioneering in this specific field, it has had to develop its own measurement methods. This requires significant knowledge and expertise that are unique to BioHarvest. The Company will utilize this knowledge throughout the development process, to measure the cannabinoid levels in the trichomes and the overall cell biomass.
- Nature of Trichomes - BioHarvest has been able to develop a unique configuration of cells with trichomes which it calls "Bio-Tricho-Bubbles" (Figure 1:) which is similar in appearance to what is called Ice Hash or Bubble Hash. Ice Hash/ Bubble Hash results from the mechanical separation of glandular trichome heads from raw Cannabis flowers (Figure 2:). BioHarvest's "Bio-Tricho-Bubbles" are similar in shape to Ice Hash/Bubble Hash but do not require a major mechanical process to separate out the glandular trichome heads from raw Cannabis flowers. BioHarvest's "Bio-Tricho-Bubbles" feature trichomes at a higher density than that of regular trichomes on a Cannabis plant (Figure 3:).
- Bioreactors - In parallel with continuing the commercialization process, and with its newly developed measurement methods, the R&D team is heavily focused on optimizing the cannabinoid levels in their unique "Bio-Tricho-Bubbles". For that purpose, a significant quantity of dedicated bioreactors (Figure 4:) are already in use producing cannabinoids. This is currently the highest priority of the R&D team where it will be applying its more than 50 people-years of cumulative experience of plant cell growth.
- Drying - Due to the unique "Bio-Tricho-Bubbles" composition of the BioHarvest cells with trichomes, the Company has commenced optimizing the drying process of these unique "Bio-Tricho-Bubbles" to minimize any potential damage to the trichome during the drying process.
Figure 1: BHSC - Unique Configuration “Bio-Tricho-Bubbles”
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6168/86872_biohar2.jpg
Figure 2: Bubble Hash – 99% Dry Mechanically Sifted Trichome Heads
To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/6168/86872_biohar4.jpg
Figure 3: Regular Trichome on Cannabis Plant
To view an enhanced version of Figure 3, please visit:
https://orders.newsfilecorp.com/files/6168/86872_biohar6.jpg
Figure 4: BHSC - “Bio-Tricho-Bubbles” Growing in Bioreactors
To view an enhanced version of Figure 4, please visit:
https://orders.newsfilecorp.com/files/6168/86872_biohar8.jpg
"We continue to make steady progress towards achieving our goals in the Cannabis vertical of the Company," said Ilan Sobel, CEO of BioHarvest, and added "We keep making history with our scientific and technological achievements in the area of plant-based cell growth. We try to communicate such achievements as frequently as possible, so as to reinforce the confidence of our shareholders. We understand the desire of the investment community to have such updates and we are consistently trying to maintain a balance between information disclosure and potential competitive impact. I am celebrating today my first anniversary at BioHarvest, and I have full confidence in our team to deliver on the goals we have set".
Yochi Hagay, CTO of BioHarvest, commented: "I am very proud of the achievements of my team. Despite all the hardship caused by the pandemic, which not only limited our capability to conduct proper work in the labs, but also restricted the availability of critical materials, the team was able to make the significant achievements described above. Plant biology is a complicated universe, but we have been consistently capable of navigating our way and delivering the required results. Obviously, biological research requires time, and we are not sparing any efforts to complete our tasks on time. I remain optimistic not only in demonstrating the feasibility of BioFarming Cannabis but also in the commercial production of cannabinoids based on our proprietary and patented plant cell growth technology".
Eitan Popper, former President & Co-Founder of MedReleaf, and current Chairman of BioHarvest's Advisory Board added: "The progress that BioHarvest's R&D team has made with Cannabis cells and Cannabis trichomes in particular, is both disruptive from an industry perspective and ground-breaking from a scientific point of view. Full scale-up and commercialization, appear to be closer than ever."
The Company is hosting a shareholder update conference via Zoom on July 8th at 2 PM Eastern Time where the achievements noted above will be discussed further. Register Now!
About BioHarvest Sciences Inc.
Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company's technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.'s objective is to also become a leading supplier of cannabis for both medicinal and legal recreational purposes.
For more information visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: [email protected]
Twitter
Facebook
LinkedIn
YouTube
Forward-Looking Statements
Information set forth in this news release includes might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance we will be able to commercialize our first Cannabis products in the first half of 2022. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. The success of the Company in demonstrating its ability to consistently grow in solution trichomes from multiple plant strains is not an assurance that the Company will be able to commence commercial production when anticipated or at all. While the company is in the process of constructing a two-ton production facility the Company's current licensing only permits scientific research. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86872